Takeda Pharmaceutical Statistics
Total Valuation
Takeda Pharmaceutical has a market cap or net worth of $52.36 billion. The enterprise value is $82.24 billion.
Important Dates
The next estimated earnings date is Wednesday, May 13, 2026, before market open.
| Earnings Date | May 13, 2026 |
| Ex-Dividend Date | Sep 30, 2025 |
Share Statistics
Takeda Pharmaceutical has 1.58 billion shares outstanding. The number of shares has increased by 0.25% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 1.58B |
| Shares Change (YoY) | +0.25% |
| Shares Change (QoQ) | +1.77% |
| Owned by Insiders (%) | 0.11% |
| Owned by Institutions (%) | 47.07% |
| Float | 1.58B |
Valuation Ratios
The trailing PE ratio is 72.69 and the forward PE ratio is 31.45.
| PE Ratio | 72.69 |
| Forward PE | 31.45 |
| PS Ratio | 1.84 |
| Forward PS | 0.02 |
| PB Ratio | 1.07 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 8.27 |
| P/OCF Ratio | 6.90 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 10.12, with an EV/FCF ratio of 12.98.
| EV / Earnings | 114.18 |
| EV / Sales | 2.89 |
| EV / EBITDA | 10.12 |
| EV / EBIT | 21.38 |
| EV / FCF | 12.98 |
Financial Position
The company has a current ratio of 1.19, with a Debt / Equity ratio of 0.71.
| Current Ratio | 1.19 |
| Quick Ratio | 0.54 |
| Debt / Equity | 0.71 |
| Debt / EBITDA | 4.09 |
| Debt / FCF | 5.46 |
| Interest Coverage | 4.62 |
Financial Efficiency
Return on equity (ROE) is 1.50% and return on invested capital (ROIC) is 2.76%.
| Return on Equity (ROE) | 1.50% |
| Return on Assets (ROA) | 2.47% |
| Return on Invested Capital (ROIC) | 2.76% |
| Return on Capital Employed (ROCE) | 4.71% |
| Weighted Average Cost of Capital (WACC) | 3.50% |
| Revenue Per Employee | $600,047 |
| Profits Per Employee | $15,177 |
| Employee Count | 47,455 |
| Asset Turnover | 0.29 |
| Inventory Turnover | 1.16 |
Taxes
In the past 12 months, Takeda Pharmaceutical has paid $587.95 million in taxes.
| Income Tax | 587.95M |
| Effective Tax Rate | 44.89% |
Stock Price Statistics
The stock price has increased by +9.05% in the last 52 weeks. The beta is 0.13, so Takeda Pharmaceutical's price volatility has been lower than the market average.
| Beta (5Y) | 0.13 |
| 52-Week Price Change | +9.05% |
| 50-Day Moving Average | 18.02 |
| 200-Day Moving Average | 15.75 |
| Relative Strength Index (RSI) | 27.52 |
| Average Volume (20 Days) | 2,948,797 |
Short Selling Information
The latest short interest is 4.73 million, so 0.30% of the outstanding shares have been sold short.
| Short Interest | 4.73M |
| Short Previous Month | 5.87M |
| Short % of Shares Out | 0.30% |
| Short % of Float | 0.30% |
| Short Ratio (days to cover) | 1.53 |
Income Statement
In the last 12 months, Takeda Pharmaceutical had revenue of $28.48 billion and earned $720.25 million in profits. Earnings per share was $0.45.
| Revenue | 28.48B |
| Gross Profit | 18.66B |
| Operating Income | 3.85B |
| Pretax Income | 1.31B |
| Net Income | 720.25M |
| EBITDA | 8.13B |
| EBIT | 3.85B |
| Earnings Per Share (EPS) | $0.45 |
Full Income StatementBalance Sheet
The company has $4.18 billion in cash and $34.58 billion in debt, giving a net cash position of -$30.40 billion or -$19.25 per share.
| Cash & Cash Equivalents | 4.18B |
| Total Debt | 34.58B |
| Net Cash | -30.40B |
| Net Cash Per Share | -$19.25 |
| Equity (Book Value) | 48.75B |
| Book Value Per Share | 30.86 |
| Working Capital | 3.23B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $7.58 billion and capital expenditures -$1.14 billion, giving a free cash flow of $6.33 billion.
| Operating Cash Flow | 7.58B |
| Capital Expenditures | -1.14B |
| Depreciation & Amortization | 4.20B |
| Net Borrowing | -1.11B |
| Free Cash Flow | 6.33B |
| FCF Per Share | $4.01 |
Full Cash Flow StatementMargins
Gross margin is 65.52%, with operating and profit margins of 13.51% and 2.53%.
| Gross Margin | 65.52% |
| Operating Margin | 13.51% |
| Pretax Margin | 4.60% |
| Profit Margin | 2.53% |
| EBITDA Margin | 28.53% |
| EBIT Margin | 13.51% |
| FCF Margin | 22.25% |